Development Overview. Qorvo and Zomedica will work in collaboration to develop (a) Instruments that meet the Specifications as set forth in the applicable Instrument SOW, (b) Cartridges that meet the Specifications as set forth in the applicable Cartridge SOW, and (c) Assays specified by Zomedica for use with the Instruments and Cartridges for the purpose of performing such Assays for use in the Field.
Development Overview. The Parties desire and intend to transition the Development of Compounds and Products from Principia to Sanofi (the “Transition”), provided that, before the completion of the Transition, Principia will conduct certain early Development activities set forth in Section 3.2 in coordination with Sanofi.
Development Overview. The Parties shall collaborate in the development of Licensed Products up until the completion of Phase I Clinical Trials in the Field globally in accordance with the Global Development Plan and Section 4.3 below. Thereafter, the Parties may continue the development collaboration or conduct development activities in their respective territories separately in accordance with Section 4.4 below.
Development Overview. Nightstar intends to progress the programmes through the necessary pre-clinical, IND/CTA enabling and clinical development phases necessary to achieve regulatory product licensure in the US and EU. The programs are in various stages of pre-clinical development and will require a significant amount of activity to get clinic ready. It is anticipated that a number of IND-enabling activities are ‘pipeline’ activities; synergistic activities applicable to all the programmes, supporting the development through to entry into clinical testing.
Development Overview. The term “
Development Overview. The following provisions relate to the overall responsibility of the parties and the PMC for the development of the Products:
2.1.1 Tris shall be responsible for delivery of all Product Schedules and Product Details for the Products to the PMC. Tris shall deliver the Development Schedule for each Product by April 1, 2005. The development of each Product and the Product Plan, shall be reviewed by the PMC. During the development and regulatory review of a Product, the PMC shall meet at the call of either Party, and as required under this Agreement, at a mutually acceptable location, or by telephone. Each Party shall bear its own costs with respect to participation in the PMC. Once the Product Details are received by the PMC, the PMC shall review and discuss: (i) all development decisions regarding the Product, including, but not limited to, clinical trials and Regulatory Approvals, Patent Challenges and (ii) deciding whether to defend, and the defense of, Infringement Claims.
2.1.2 In the case of any potential patent litigation (including any litigation arising in connection with a Patent Challenge), Interpharm shall keep the PMC apprised of (i) whether it will defend an Infringement Claim and the defense of such claim, and whether it will prosecute, and prosecution of, a Tris Infringement Claim and (ii) whether it will proceed with, and/or proceeding with, a Patent Challenges.
2.1.3 In the case of a Tris Infringement Claim, if Interpharm elects not to prosecute such a Claim, Tris shall have the right to prosecute the Claim on its own. In that event, (i) Tris shall keep Interpharm reasonably apprised of the progress and status thereof on an ongoing basis; and (ii) Tris shall have the right to recover the Tris Litigation Costs associated with such litigation in accordance with Section 3.1.1, below; provided, however, that (i) such litigation relates to one or more Products, and (ii) the infringement underlying the Tris Infringement Claim would adversely affect Interpharm's Commercialization of a Product.
Development Overview. On 22 July 2016, Urbis Pty Ltd lodged a development application (Test of Adequacy submission) on behalf of Xxxx. The development application seeks consent for a mixed use development. The objectives of the development application and the outcomes sought to be delivered through the Development Application, include the redevelopment of the land to accommodate a high quality mixed use development of a large site in the Eastwood Town Centre that successfully integrates with surrounding land uses, whilst activating adjoining public domain. The redevelopment comprises: - Retail and commercial uses; - Residential accommodation in the form of shop top housing; - Car parking for residents, retail, and commercial uses; and - Publicly accessible pedestrian links between Xxxx Street and Xxxxxxxx Street. Variations to the Height of Building (HOB) standards under Clause 4.3 of the Ryde Local Environmental Plan 2014 (RLEP, 2014) are proposed and a Request for Exceptions to the HOB standards accompanies the development application. Further information on the proposed development application is provided in the Statement of Environmental Effects (SEE) and supporting documents.
Development Overview. Janie’s Garden I is an existing 86 unit development with 14 residential buildings consisting of townhomes, duplexes and garden apartments, and located in Sarasota, Sarasota County, Florida. The unit mix includes 15 one bedroom/one bathroom units, 9 two bedroom/one bathroom units, 47 two bedroom/one and one-half bathroom, 9 three bedroom/two bathroom units and 6 four bedroom/two bathroom units. The demographic commitment is Family. Of the 86 units, 20 are market rate units, 66 are Low Income Housing Tax Credit (“LIHTC”) units, of which 26 are public housing units.. The Florida Housing set asides are as follows per the First Amendment to the Extended Low-Income Housing Agreement (“ELIHA”), dated March 18, 2010: 20% (18 Extremely Low Income “XXX” units) at or below 30% Area Median Income (“AMI”) for 50 years. 56% (48 units) at or below 60% AMI for 50 years (000) 000-0000 • (000) 000-0000 • 0000 X. Xxxxxxx Xx., Xxxxx #000, Xxxxx, XX 00000 • xxx.xxxxxxxxxx.xxx
Development Overview. On a Category 1 Target‑by‑ Category 1 Target basis, Wave will use Commercially Reasonable Efforts to Develop all Category 1 Compounds, Category 1 Products, and Companion Diagnostics directed to the applicable Category 1 Target in accordance with this Agreement, including the applicable Candidate Category 1 Development Plan or Licensed Category 1 Development Plan (each a “Category 1 Development Program”). Notwithstanding the foregoing, the Parties may agree upon certain activities that Takeda will conduct under a Category 1 Development Plan for a Category 1 Development Program. Each Category 1 Development Program will include the [***]. Each Party will conduct all Development of Category 1 Compounds, Category 1 Products, and Companion Diagnostics directed to the applicable Category 1 Target as part of the applicable Category 1 Development Program and in accordance with the applicable Category 1 Development Plan [***].
Development Overview. 10 2.2 Overall Management of Development Efforts.......................10 2.3
